Delaware Crossing Investor Group
Signal active
Investment Firm
Overview
Delaware Crossing Investor Group is a network of former and current executives and entrepreneurs who provide counsel and capital to early-stage and other growth-oriented companies.
Delaware Crossing Investor Group is a membership organization of qualified investors who play an active role in the sourcing of prospective portfolio companies, managing the investment process and serving on the board of directors of portfolio companies.
Highlights
Founded
2005
Industry
Employees
11-50
Investment
14
Lead Investment
0
Exits
5
Stages
Seed, Early Stage Venture
Investor Type
Angel Group
Location
Doylestown, Pennsylvania, United States, North America
Contact Information
Social
Profile Resume
Delaware Crossing Investor Group, established in 2005 and headquartered in United States, North America., specializes in Seed, Early Stage Venture investments across Biotechnology, Health Care, Pharmaceutical, Financial Services, Venture Capital, Life Science, Enterprise Software, Nanotechnology, Packaging Services, Finance. The organization boasts a portfolio of 14 investments, with an average round size of $3.7M and 5 successful exits. Their recent investments include Novira Therapeutics, BioAdvance, Robin Hood Ventures, NanoPack, Mid Atlantic Angel Fund. The highest investment round they participated in was $3.7B. Among their most notable exits are Novira Therapeutics and BioAdvance. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Delaware Crossing Investor Group has made 14 investments. Their most recent investment was on Jan 12, 2016, when Life.io raised $1.5M.
Delaware Crossing Investor Group has made 7 diversity investments. Their most recent diversity investment was on Oct 03, 2019, when Ophidion raised $1.7M.
investments
14
Diversity investments
7
Lead investments
0
Number of exits
5
Investments
14
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Oct 03, 2019 | Ophidion | Biotechnology | 1.7M |
| Aug 25, 2021 | - | - | 4.3M |
| Sep 10, 2022 | - | - | 2.5M |
| Apr 21, 2023 | Measure Studio | Social Media | null |
Exits
5
Funding Timeline
Funding rounds
14
Investors
0
Funds
0
Funding Rounds
14
Delaware Crossing Investor Group has raised 14 rounds. Their latest funding was raised on Apr 21, 2023 from a Seed Round - Measure Studio round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Oct 03, 2019 | Seed Round - Ophidion | - | 1.7M | - |
| Aug 25, 2021 | Series A - VESTECK | - | 4.3M | - |
| Sep 10, 2022 | Venture Round - SunRay Scientific Inc. | - | 2.5M | - |
| Apr 21, 2023 | Seed Round - Measure Studio | - | 0 | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
N/A
Recent Activity
Funding Round
Apr 21, 2023
Measure Studio raised an undisclosed amount on 2023-04-21 in Seed Round
Funding Round
Sep 10, 2022
SunRay Scientific Inc. raised $2500000 on 2022-09-10 in Venture Round
Funding Round
Aug 25, 2021
VESTECK raised $4300000 on 2021-08-25 in Series A
Funding Round
Oct 03, 2019
Ophidion raised $1700000 on 2019-10-03 in Seed Round
Funding Round
Feb 21, 2018
ThruPore Technologies raised $540000 on 2018-02-21 in Seed Round